X4 Pharmaceuticals, Inc. (XFOR) compared with its closest peers (EDIT, OCGN, DNA, CMPX, VACH). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Editas Medicine, Inc. (EDIT) | $476.10M | -1.1 |
| Ocugen, Inc. (OCGN) | $474.75M | — |
| Ginkgo Bioworks Holdings, Inc. (DNA) | $455.98M | -1.5 |
| Compass Therapeutics, Inc. (CMPX) | $431.31M | -12.8 |
| Voyager Acquisition Corp. (VACH) | $415.93M | 41.8 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $399.98M | -5.3 |
| Fennec Pharmaceuticals Inc. (FENC) | $395.91M | 227.9 |
| Century Therapeutics, Inc. (IPSC) | $373.92M | -7.0 |
| Palisade Bio, Inc. (PALI) | $367.71M | -7.9 |
| Sutro Biopharma, Inc. (STRO) | $347.32M | -0.5 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
XFOR overview · XFOR earnings · XFOR financials · XFOR KPIs · XFOR investor relations · XFOR ownership · XFOR filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.